Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01717209 · ClinicalTrials.gov registry record · Phase 4
Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement
A Phase 4 study of Heart Failure, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT01717209: Completed Phase 4 study of Heart Failure, sponsored by Stanford University.
NCT01717209 is a Phase 4 study of Heart Failure that has completed, run by Stanford University. The registered enrollment target is 14 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01717209, a Phase 4 study of Heart Failure, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Research study evaluating the individual and combined effects of inhaled nitric oxide (iNO) and inhaled prostacyclin (iPGI2), on the function of the right heart after surgery for either heart transplant or for left ventricular assist device (LVAD) placement. The investigators hope to learn if these two medications, when given together after surgery, improve right heart function by lowering blood vessel pressures in the lungs. The investigators hope to learn if the combined effects of these two medications are better than either medication used alone. Participants were selected as a possible participant in this study because right heart problems are common during and after surgery for heart transplant and for LVAD placement. In addition, iNO is always given during and after these two types of surgeries at Stanford to help improve how the right heart functions.
Conditions Studied
Interventions
- DRUG Nitric Oxide
- DRUG Prostacyclin
Study Locations (1)
California
- Stanford Hospital and Clinics - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01717209
The ClinicalTrials.gov registry entry for NCT01717209 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Nitric Oxide is the first listed.
NCT01717209 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01717209 about?
NCT01717209 is a clinical study titled "Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement". Research study evaluating the individual and combined effects of inhaled nitric oxide (iNO) and inhaled prostacyclin (iPGI2), on the function of the right heart after surgery for either heart transplant or for left ventricular assist device (LVAD) placement. The investigators hope to learn if these ...
What is the current status of trial NCT01717209?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2012-10. Estimated completion is 2013-10.
What conditions does trial NCT01717209 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT01717209?
The interventions under investigation include: Nitric Oxide (DRUG), Prostacyclin (DRUG).
Who is sponsoring clinical trial NCT01717209?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01717209 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.